Nieminen P, Paasivuo R, Saksela E
J Immunol. 1982 Mar;128(3):1097-101.
A monoclonal hybridoma antibody of IgGIa subclass was produced by fusing NS-1 myeloma cells with spleen cells of a mouse immunized with human LGL cells. This hybridoma antibody, termed NK-8, was reactive by indirect immunofluorescence with 33% of peripheral blood LGL cells and 70% of LGL forming conjugates with K-562 cells. Monocytes, granulocytes, and other lymphocytes were nonreactive. In iodinated protein A binding assays NK-8 was nonreactive with all kinds of leukemia and lymphoma lines tested and showed activity only against LGL cells. NK-8 inhibited the LGL-mediated cytotoxicity against K-562 cells by 50 to 60% without complement and inhibited the K-562 induced interferon production from the LGL population. However, the spontaneous cytotoxicity against human skin fibroblasts was augmented if the effector cells were pretreated with NK-8.
通过将NS-1骨髓瘤细胞与用人LGL细胞免疫的小鼠脾细胞融合,制备出了IgGIa亚类的单克隆杂交瘤抗体。这种杂交瘤抗体名为NK-8,通过间接免疫荧光法可与33%的外周血LGL细胞以及70%与K-562细胞形成结合物的LGL细胞发生反应。单核细胞、粒细胞和其他淋巴细胞无反应。在碘化蛋白A结合试验中,NK-8与所检测的各类白血病和淋巴瘤细胞系均无反应,仅对LGL细胞有活性。NK-8在无补体的情况下可将LGL介导的对K-562细胞的细胞毒性抑制50%至60%,并抑制K-562诱导的LGL群体产生干扰素。然而,如果效应细胞用NK-8预处理,则对人皮肤成纤维细胞的自发细胞毒性会增强。